Innovative Lentiviral Packaging Systems
The Lenti-X 4th generation packaging systems are optimized for viral yield, ease-of-use, and safety. Use these systems to produce ultra-high titers of lentivirus. Two pseudotype options are available:
- VSV-G lentiviral packaging—produces VSV-G pseudotyped lentivirus, which readily infects virtually all types of cells. A non-integrating version is also available.
- Ecotropic lentiviral packaging—produces lentivirus pseudotyped with the MLV ecotropic envelope glycoprotein, which limits transduction to mouse and rat cells.
High Lentiviral Titer
Our Lenti-X HTX packaging systems generate lentiviral titers that far exceed most other commercially available packaging systems—you can expect titers of 107–108 infectious units (IFU) per ml, that’s 25 times what other popular systems generate.
How is such high titer achieved?
- Optimized composition—Lentiviral packaging and nonviral components provided as a proprietary suite of 5 vectors (Figure 1), premixed in the ideal ratio to maximize virus production.
- Tetracycline transactiviation—High-level expression of packaging components using Tet-system promoters.
- Optimized transfection—Xfect™ reagent consistently results in >95% transduction efficiency for HEK 293T cells, allowing high expression of packaging components.
- Specialized Lenti-X 293T cell line—Highly transfectable cells selected to provide titers as high as 108 IFU/ml.
Figure 1. Clontech’s Lenti-X HTX Packaging Systems consist of 5 separate vectors (A). High expression of essential viral components are driven by the Tet-Off and Tat transactivators. The pol gene is fused to vpr to ensure transport of the reverse transcriptase/integrase protein into the recombinant viral particle. Other 3rd generation systems (B) do not contain separate gag and pol sequences. Not all vector elements are shown.
How much packaged lentivirus can be obtained from a single Lenti-X HTX packaging reaction?
A single Lenti-X HTX packaging reaction generates 10 ml of unconcentrated lentiviral supernatant at 107–108 IFU/ml. Leading competitor systems produce far less (Figure 2).
Figure 2. Lenti-X (Panel A) and a competitor’s packaging system (Panel B) were each used with Lenti-X 293T cells to generate lentiviral vectors that express ZsGreen1. The supernatant was used for transduction of HeLa cells—10 µl of the Lenti-X packaging reaction was able to transduce the majority of the cells, whereas 10 µl of the competitor’s supernatant transduced only a small percentage of cells.
The maximum titer obtained by our scientists was ~5 x 108 IFU/ml (unconcentrated supernatant), as determined by analysis of ZsGreen1 expression from a pLVX backbone by flow cytometry. The cPPT/CTS and WPRE sequences and the wild-type 5' LTRs on pLVX vectors contribute to higher titers. In 13 independent packaging reactions performed with 10 different fluorescent protein constructs, the average titer obtained for pLVX vectors packaged using the Lenti-X system was 1.85 x 108 IFU/ml, as determined by flow cytometric analysis of transduced HeLa cells.
Easy-to-Use Systems for Lentiviral Packaging
To use, a lentiviral vector and the Lenti-X HTX Packaging Mix are cotransfected into Lenti-X 293T Cells. High titer lentiviral supernatants are ready for use 48 hours after transfection. The resulting high titer lentiviral particles are ready-to-use, there’s no need to concentrate virus.
What type of cells should be used for packaging?
The Lenti-X HTX Packaging Systems are optimized for use with Lenti-X 293T Cells, a clone selected at Clontech for its ability to generate high titer lentivirus, and 293T cells. HEK 293 and 293FT cells can be used but will produce lower titers of packaged lentiviral particles (Figure 2).
Figure 3. Lenti-X 293T cells produce over 6X more virus than 293FT cells, and up to 30X more virus than the HEK 293 cells.
What type of lentiviral vectors are compatible with this system?
We have not tested all vectors, but in principle, any HIV-1-based vector should be efficiently packaged using this system, resulting in high titer lentivirus. For example, a ZsGreen1 cassette in the pLenti6/V5 vector (Invitrogen)—a vector that lacks the WPRE and cPPT/CTS sequence elements and utilizes self-inactivating (SIN) LTRs—titers of >3 x 107 IFU/ml were obtained as determined by flow cytometry. Since the Lenti-X system utilizes Tat transactivation, lentiviral vectors that utilize HIV-1 5' LTRs (such as pLVX vectors) will generate higher titers than those containing other LTRs. Vectors lacking WPRE and/or cPPT/CTS sequences yield consistently lower titers than Clontech pLVX vectors.
Note: Use of vector systems other than Clontech’s may require additional rights from third parties. You should evaluate whether permission from any third party is required for your intended use.
Improved Safety Profile
For lentiviral transfer vectors to generate DNA-mobilizing, replication-competent lentivirus (RCL), several additional viral sequences must be acquired from the packaging plasmids via recombination (i.e., the structural genes gag-pro and env; and the reverse transcriptase/integrase gene, pol). In 3rd-generation systems, gag-pro and pol sequences are in the same transcriptional unit, while env (VSV-G) is on a separate plasmid. Therefore, in these systems, generation of RCL requires two recombination events. With Lenti-X Packaging Systems, gag-pro and pol are further separated onto two plasmids (Figure 1), such that three low-frequency recombination events would be needed to generate RCL. Click here for more safety information.
|Lenti-X™ HTX Packaging System||4th Generation, high titer packaging system for generating VSV-g pseudotyped lentivirus||Learn More >>|
|Lenti-X™ HTX Ecotropic Packaging System||4th Generation, high titer packaging system for generating ecotropic pseudotyped lentivirus||Learn More >>|
|Lenti-X™ HTX Packaging System (Integrase Deficient)||Mutant integrase minimizes proviral integration||Learn More >>|
|Lenti-X™ 293T Cell Line||293T clone selected for high titer lentivirus production||Learn More >>|